Home Page - Slider
More than 25 years of testing experience and expertise
Evolving personalize testing for you
Because Knowledge is a Powerful Tool
Dedicated to helping educate patients and inform the public about oncology diagnostic testing.
Prepare for visits with your doctor or a genetic counselor by learning about testing.
Integrated Oncology Highlights
Integrated Oncology now offers the FDA-approved cobas EGFR mutation test V2 in both FFPE tissue and plasma samples
Now the Largest Open BRCA Datashare of Curated BRCA Variants Clinically Suitable for Patient Management
This test was recently FDA-approved as a complementary diagnostic assay that may help identify patients with locally advanced or metastatic urothelial carcinoma more likely to respond to treatment with TecentriqTM(atezolizumab).
This test was recently FDA approved as a companion diagnostic assay to aid in identifying metastatic NSCLC patients for treatment with KEYTRUDA® (pembrolizumab).
This test was recently FDA-approved as a complementary diagnostic test to help physicians determine which patients may benefit most with OPDIVO® (nivolumab).
Prosigna Breast Cancer Prognostic Gene Signature Assay, which is based on the PAM50 gene signature, is an FDA 510(k) cleared assay to assess a patient’s risk of distant recurrence of disease.
IntelliGEN® Oncology Therapeutic Panel (NGS) assay provides an assessment of targetable mutations within a panel of cancer genes known to be involved in the development, progression and/or treatment of cancers.